Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer.

Journal

NPJ breast cancer
ISSN: 2374-4677
Titre abrégé: NPJ Breast Cancer
Pays: United States
ID NLM: 101674891

Informations de publication

Date de publication:
04 Apr 2024
Historique:
received: 19 12 2023
accepted: 22 03 2024
medline: 5 4 2024
pubmed: 5 4 2024
entrez: 4 4 2024
Statut: epublish

Résumé

To evaluate the role of chemotherapy in stage IA triple-negative breast cancer, we conducted a retrospective population-based study including 8601 patients. The use of chemotherapy significantly increased from 2010 to 2019 in patients with T1b and T1c tumors (p = 0.001 and p < 0.001, respectively). Receipt of chemotherapy was associated with improved breast cancer-specific survival (BCSS, adjusted hazard ratio = 0.70; p = 0.006), particularly in patients with T1c tumors (5-year BCSS 94.5% vs. 91.2%).

Identifiants

DOI: 10.1038/s41523-024-00634-6 PMID: 38575691
pubmed: 38575691
doi: 10.1038/s41523-024-00634-6
pii: 10.1038/s41523-024-00634-6
doi:

Types de publication

Journal Article

Langues

eng

Pagination

26

Informations de copyright

© 2024. The Author(s).

Références

Lin, N. U. et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 118, 5463–5472, https://doi.org/10.1002/cncr.27581 (2012).
doi: 10.1002/cncr.27581 pubmed: 22544643
Dent, R. et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 13, 4429–4434, https://doi.org/10.1158/1078-0432.CCR-06-3045 (2007).
doi: 10.1158/1078-0432.CCR-06-3045 pubmed: 17671126
NCCN Clinical Practice Guidelines in Oncology. Breast Cancer Guidelines Version 5.2023. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
Vaz-Luis, I. et al. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J. Clin. Oncol. 32, 2142–2150, https://doi.org/10.1200/JCO.2013.53.1608 (2014).
doi: 10.1200/JCO.2013.53.1608 pubmed: 24888816 pmcid: 4076026
Du, Z. L. et al. Evaluation of a beneficial effect of adjuvant chemotherapy in patients with stage I triple-negative breast cancer: a population-based study using the SEER 18 database. Breast Cancer Res. Treat. 183, 429–438, https://doi.org/10.1007/s10549-020-05776-2 (2020).
doi: 10.1007/s10549-020-05776-2 pubmed: 32647940
Zhai, Z. et al. Evaluation of adjuvant treatments for T1 N0 M0 triple-negative breast cancer. JAMA Netw. Open 3, e2021881, https://doi.org/10.1001/jamanetworkopen.2020.21881 (2020).
doi: 10.1001/jamanetworkopen.2020.21881 pubmed: 33211105 pmcid: 7677762
Shen, K. et al. Impact of adjuvant chemotherapy on T1N0M0 breast cancer patients: a propensity score matching study based on SEER database and external cohort. BMC Cancer 22, 863, https://doi.org/10.1186/s12885-022-09952-z (2022).
doi: 10.1186/s12885-022-09952-z pubmed: 35941565 pmcid: 9358893
Carbajal-Ochoa, W., Bravo-Solarte, D. C., Bernal, A. M. & Anampa, J. D. Benefit of adjuvant chemotherapy in lymph node-negative, T1b and T1c triple-negative breast cancer. Breast Cancer Res. Treat. 203, 257–269, https://doi.org/10.1007/s10549-023-07132-6 (2023).
doi: 10.1007/s10549-023-07132-6 pubmed: 37833449

Auteurs

Paolo Tarantino (P)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Department of Oncology and Onco-Hematology, University of Milan, Milan, Italy.
ORCID: 0000-0001-8686-0228

Julieta Leone (J)

Grupo Oncológico Cooperativo del Sur, Neuquén, Argentina.

Carlos T Vallejo (CT)

Grupo Oncológico Cooperativo del Sur, Neuquén, Argentina.

Rachel A Freedman (RA)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.

Adrienne G Waks (AG)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.

Olga Martínez-Sáez (O)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.

Ana Garrido-Castro (A)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
ORCID: 0000-0002-5989-6636

Filipa Lynce (F)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
ORCID: 0000-0001-6615-7076

Nabihah Tayob (N)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.

Nancy U Lin (NU)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.

Sara M Tolaney (SM)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
ORCID: 0000-0002-5940-8671

Jose P Leone (JP)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. JoseP_Leone@dfci.harvard.edu.
Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA. JoseP_Leone@dfci.harvard.edu.
Harvard Medical School, Boston, MA, USA. JoseP_Leone@dfci.harvard.edu.
ORCID: 0000-0002-8537-652X

Classifications MeSH